Rockefeller Capital Management L.P. Has $2.90 Million Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Rockefeller Capital Management L.P. trimmed its stake in Laboratory Co. of America Holdings (NYSE:LH) by 5.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,644 shares of the medical research company’s stock after selling 793 shares during the period. Rockefeller Capital Management L.P.’s holdings in Laboratory Co. of America were worth $2,900,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Graney & King LLC bought a new position in Laboratory Co. of America during the fourth quarter worth $26,000. Fortitude Family Office LLC grew its holdings in Laboratory Co. of America by 312.5% during the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after acquiring an additional 100 shares during the period. Geneos Wealth Management Inc. raised its position in shares of Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock worth $39,000 after acquiring an additional 127 shares in the last quarter. Human Investing LLC acquired a new position in shares of Laboratory Co. of America in the 4th quarter valued at about $39,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Laboratory Co. of America during the 4th quarter valued at about $44,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Laboratory Co. of America Stock Performance

NYSE LH opened at $217.25 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. The company has a market capitalization of $18.18 billion, a PE ratio of 24.63, a price-to-earnings-growth ratio of 1.71 and a beta of 0.99. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $258.59. The company has a 50-day simple moving average of $237.54 and a 200 day simple moving average of $234.73.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, research analysts predict that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 11th. Investors of record on Thursday, May 29th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.33%. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,121 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the sale, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Amy B. Summy sold 758 shares of Laboratory Co. of America stock in a transaction on Friday, March 28th. The shares were sold at an average price of $231.67, for a total value of $175,605.86. Following the completion of the transaction, the executive vice president now owns 5,302 shares of the company’s stock, valued at approximately $1,228,314.34. This trade represents a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,258 shares of company stock valued at $3,518,177 over the last three months. 0.84% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LH has been the topic of several recent analyst reports. Citigroup raised Laboratory Co. of America from a “neutral” rating to a “buy” rating and boosted their price target for the company from $250.00 to $300.00 in a research note on Tuesday, March 4th. Evercore ISI raised shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $260.00 to $265.00 in a research report on Tuesday, January 7th. Piper Sandler boosted their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Jefferies Financial Group increased their price objective on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, Barclays dropped their target price on Laboratory Co. of America from $260.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $268.77.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.